Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 5/20 | 0.41 |
| ▸ | MMP2 | P08253 | 4/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | MMP3 | P08254 | 4/20 | 0.38 |
| ▸ | MMP8 | P22894 | 4/20 | 0.38 |
| ▸ | MMP1 | P03956 | 3/20 | 0.38 |
| ▸ | MMP12 | P39900 | 2/20 | 0.38 |
| ▸ | MMP14 | P50281 | 2/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3381510 | 1.00 | PTGFR (0.49) | PTGFRMMP9MMP2HSD11B1DRD2 | |
| SCHEMBL3382814 | 1.00 | PTGFR (0.49) | PTGFRMMP9MMP2HSD11B1DRD2 | |
| SCHEMBL3381695 | 1.00 | PTGFR (0.49) | PTGFRMMP9MMP2HSD11B1DRD2 | |
| SCHEMBL29873273 | 1.00 | PTGFR (0.49) | PTGFRMMP9MMP2HSD11B1DRD2 | |
| SCHEMBL3380122 | 1.00 | PTGFR (0.49) | PTGFRMMP9MMP2HSD11B1DRD2 | |
| SCHEMBL3383880 | 0.93 | PTGFR (0.42) | PTGFRHSD11B1DRD2S1PR2S1PR4 | |
| SCHEMBL3383876 | 0.93 | PTGFR (0.42) | PTGFRHSD11B1DRD2S1PR2S1PR4 | |
| SCHEMBL3386587 | 0.92 | KMT2A (0.43) | PTGFRMMP2HSD11B1DRD2MMP3 | |
| SCHEMBL3386588 | 0.92 | KMT2A (0.43) | PTGFRMMP2HSD11B1DRD2MMP3 | |
| SCHEMBL3385850 | 0.91 | PTGFR (0.46) | PTGFRHSD11B1DRD2S1PR2S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487442-B1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | MERCK SERONO SA (CH) | 2010-12-01 | — | — | EP | claimed |
| US-20050215605-A1 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor | MERCK SERONO SA (CH) | 2005-09-29 | — | — | US | claimed |
| US-8415480-B2 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor | MERCK SERONO SA (CH) | 2013-04-09 | — | — | US | disclosed |
| EP-1487442-B1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | MERCK SERONO SA (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20090215749-A9 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20080255094-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2008-10-16 | — | — | US | disclosed |
| US-20050215605-A1 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor | MERCK SERONO SA (CH) | 2005-09-29 | — | — | US | disclosed |
| EP-1487442-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | Applied Research Systems ARS Holding N.V. (AN) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082278-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215749-A9 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | PTGER4, PTGER2, PTGER1 | PTGFR 9/4885MMP9 4351/4885MMP2 2710/4885 |
| US-20080255094-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | PTGER4, PTGER2, PTGER1 | PTGFR 9/4885MMP9 4351/4885MMP2 2710/4885 |
| US-20050215605-A1 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor | TBXA2R, CNR2, PTGDR | PTGFR 16/4885MMP9 4645/4885MMP2 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.